Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Omeros Corporation (OMER)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Omeros Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.34B
$28.63HealthcareDelayed quote: Oct 6, 2026, 1:10 PM EDT
Omeros Corporation logo
OMER
Omeros Corporation
$1.34B
$18.52HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT

Total return — COAG vs OMER

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)OMER +25.5% (+25.5%/yr)OMER compounded faster over this window
6080100120140160Start $100$90$125
COAG OMER

COAG vs OMER: by the numbers

  • •OMER is the larger company ($1.34B vs $1.34B market cap).
  • •OMER is profitable (324.88% net margin) while COAG runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCOAGOMER
P/E ratioN/A10.77
Forward P/EN/A20.43
P/S ratioN/A34.89
P/B ratio2.94N/A

Profitability

MetricCOAGOMER
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%324.88%
ROIC-38.09%-32.06%

Growth (annualized)

MetricCOAGOMER
Revenue CAGR (5Y)N/A0.90%
Total return CAGR (5Y)N/A21.70%

Frequently asked

Is COAG or OMER more profitable?
OMER runs the higher net margin — COAG at 0.00% versus OMER at 324.88%.

Go deeper

Full COAG analysisFull OMER analysisInteractive comparison tool

Dig into the metrics

Omeros P/E ratioHemab Therapeutics Holdings, Inc. Common Stock ROEOmeros ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginOmeros operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthOmeros revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowOmeros free cash flow

Hemab Therapeutics Holdings, Inc. Common Stock & Omeros appear in these rankings

Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.